keyword
MENU ▼
Read by QxMD icon Read
search

anti-IgE

keyword
https://www.readbyqxmd.com/read/29315922/the-use-of-omalizumab-in-allergen-immunotherapy
#1
Jennifer A Dantzer, Robert A Wood
Although omalizumab (anti-IgE) is currently only approved for the treatment of asthma and chronic idiopathic urticaria, it has also been studied as an off-label treatment for numerous allergic conditions, including use as an adjunct to allergen immunotherapy in the treatment of allergic rhinitis, asthma, venom hypersensitivity, and food allergy. We conducted a review of publications involving the use of omalizumab with allergen immunotherapy, by searching PubMed with key search terms of "omalizumab" and "immunotherapy...
January 5, 2018: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29295972/trapping-ige-in-a-closed-conformation-by-mimicking-cd23-binding-prevents-and-disrupts-fc%C3%AE%C2%B5ri-interaction
#2
Frederic Jabs, Melanie Plum, Nick S Laursen, Rasmus K Jensen, Brian Mølgaard, Michaela Miehe, Marco Mandolesi, Michèle M Rauber, Wolfgang Pfützner, Thilo Jakob, Christian Möbs, Gregers R Andersen, Edzard Spillner
Anti-IgE therapeutics interfere with the ability of IgE to bind to its receptors on effector cells. Here we report the crystal structure of an anti-IgE single-domain antibody in complex with an IgE Fc fragment, revealing how the antibody inhibits interactions between IgE and the two receptors FcεRI and CD23. The epitope overlaps only slightly with the FcεRI-binding site but significantly with the CD23-binding site. Solution scattering studies of the IgE Fc reveal that antibody binding induces a half-bent conformation in between the well-known bent and extended IgE Fc conformations...
January 2, 2018: Nature Communications
https://www.readbyqxmd.com/read/29290750/an-update-on-anti-ige-therapy-in-pediatric-respiratory-diseases
#3
REVIEW
Amelia Licari, Riccardo Castagnoli, Elisa Panfili, Alessia Marseglia, Ilaria Brambilla, Gian Luigi Marseglia
Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. In addition, new experimental evidence suggests that omalizumab may also interfere with the cellular and molecular mechanisms underlying airway remodeling...
March 2017: Current Respiratory Medicine Reviews
https://www.readbyqxmd.com/read/29279058/the-effect-of-omalizumab-treatment-on-the-low-affinity-immunoglobulin-e-receptor-cd23-fc-epsilon-rii-in-patients-with-severe-allergic-asthma
#4
Miri Assayag, Shabtai Moshel, Martin Kohan, Neville Berkman
BACKGROUND: Omalizumab is an anti-immunoglobulin E (IgE) monoclonal antibody used in the treatment of severe asthma. Its therapeutic efficacy is primarily attributed to reduction of serum-free IgE and in the expression of high-affinity IgE receptor, fc epsilon RI. However, its effect on the low-affinity IgE receptor fc epsilon RII/CD23 in vivo has not been evaluated. AIM: To determine whether CD23 plays a role in the inflammatory process in severe uncontrolled asthma and whether anti-IgE therapy modulates fc epsilon RII/CD23 expression in these patients...
January 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/29274211/sensitization-to-the-storage-mites-lepidoglyphus-destructor-and-tyrophagus-putrescentiae-acari-sarcoptiformes-astigmatina-in-a-suburban-population-in-southern-poland
#5
Justyna Jakubas-Zawalska, Marek Asman, Krzysztof Solarz
Mite infestation of stored products is a serious threat to food safety and public health. These stored product mites are not only serious pests of stored food but also cause allergies in humans. Thirty serum samples from patients living in suburban areas of Upper Silesia (South Poland) were tested for sensitization to two species of storage mites: Lepidoglyphus destructor [LD] and Tyrophagus putrescentiae [TP]. Patient antibodies against particular antigens were identified using anti-human anti-IgE monoclonal antibodies...
2017: Annals of Parasitology
https://www.readbyqxmd.com/read/29249187/an-update-on-the-management-of-aspirin-exacerbated-respiratory-disease
#6
Ji-Ho Lee, Chang-Gyu Jung, Hae-Sim Park
Clinical features of aspirin-exacerbated respiratory disease (AERD) consist of moderate to severe asthma associated with chronic rhinosinusitis (CRS), which are derived from overproduction of cysteinyl leukotrienes along with chronic type 2 mediated inflammation in the upper and lower airway mucosa. Area covered: This review provides recent up-to-date information regarding phenotypes of AERD and encompasses comprehensive diagnostic methods and treatment options. To confirm the diagnosis of AERD, provocation testing via nasal, inhalation or the oral route of aspirin remains the gold standard; in vitro diagnostic methods are still not available...
December 18, 2017: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/29249138/transient-hair-loss-in-patients-with-chronic-spontaneous-urticaria-treated-with-omalizumab
#7
M Noshela Ghazanfar, S F Thomsen
Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect...
November 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29242014/anti-ige-treatment-with-oral-immunotherapy-in-multifood-allergic-participants-a-double-blind-randomised-controlled-trial
#8
Sandra Andorf, Natasha Purington, Whitney M Block, Andrew J Long, Dana Tupa, Erica Brittain, Amanda Rudman Spergel, Manisha Desai, Stephen J Galli, Kari C Nadeau, R Sharon Chinthrajah
BACKGROUND: Despite progress in single food oral immunotherapy, there is little evidence concerning the safety and efficacy of treating individuals with multiple food (multifood) allergies. We did a pilot study testing whether anti-IgE (omalizumab) combined with multifood oral immunotherapy benefited multifood allergic patients. METHODS: We did a blinded, phase 2 clinical trial at Stanford University. We enrolled participants, aged 4-15 years, with multifood allergies validated by double-blind, placebo-controlled food challenges to their offending foods...
December 11, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29225187/prostaglandin-d2-generation-from-human-lung-mast-cells-is-catalysed-exclusively-by-cyclooxygenase-1
#9
Bandar K Baothman, Jennifer Smith, Linda J Kay, S Kim Suvarna, Peter T Peachell
Mast cells are an exceptionally rich source of prostaglandin D2 (PGD2). PGD2 is pro-inflammatory and can cause bronchoconstriction. The enzyme cyclooxygenase (COX) is central to the generation of prostanoids such as PGD2. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX. COX exists as two isoforms, COX-1 and COX-2. The principal aim of this study was to establish whether COX-1 and/or COX-2 mediates PGD2 generation from human lung mast cells. Mast cells were isolated from human lung tissue and purified by flotation over Percoll and immunomagnetic bead separations...
December 7, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29213221/omalizumab-in-children-with-severe-allergic-asthma-the-italian-real-life-experience
#10
Amelia Licari, Riccardo Castagnoli, Chiara Denicolò, Linda Rossini, Manuela Seminara, Lucia Sacchi, Giorgia Testa, Mara De Amici, Gian Luigi Marseglia
Background: Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. To date, omalizumab is the only biological drug currently licensed as add-on therapy in children aged > 6 years with moderate-to-severe and severe allergic asthma uncontrolled after treatment with high dose of inhaled corticosteroids plus long-acting inhaled beta2-agonist. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies...
March 2017: Current Respiratory Medicine Reviews
https://www.readbyqxmd.com/read/29211611/pregnancy-associated-plasma-protein-a-papp-a-levels-in-patients-with-severe-allergic-asthma-are-reduced-by-omalizumab
#11
Ismet Bulut, Zeynep F Ozseker, Abdurrahman Coskun, Mustafa Serteser, Ibrahim Unsal
BACKGROUND: Remodeling is a crucial feature of severe asthma and may be associated with activation of the allergic cascade by immunoglobulin E (IgE). Omalizumab, an anti-IgE monoclonal antibody, effectively targets the severe allergic asthma phenotype. Pregnancy-associated plasma protein-A (PAPP-A) is an insulin-like growth factor binding protein-4 (IGFBP-4) protease, increasing local insulin-like growth factor (IGF)-1 concentrations, which in turn initiating a cascade involved in the regulation of cell growth, differentiation, and proliferation in various tissues...
December 6, 2017: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/29208545/il-24-is-a-common-and-specific-autoantigen-of-ige-in-patients-with-chronic-spontaneous-urticaria
#12
Oliver Schmetzer, Elisa Lakin, Fatih A Topal, Patricia Preusse, Denise Freier, Martin K Church, Marcus Maurer
BACKGROUND: The efficacy of omalizumab (anti-IgE) and increased IgE levels in patients with chronic spontaneous urticaria (CSU) suggest autoallergic mechanisms. OBJECTIVE: We sought to identify autoallergic targets of IgE in patients with CSU. METHODS: Serum samples of patients with CSU together with those of patients with idiopathic anaphylaxis and healthy control subjects (7 of each) were screened for IgE autoantibodies by using an array of more than 9000 proteins...
December 5, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29191361/comparing-the-effects-of-fluticasone-anti-ige-and-anti-tnf-treatments-in-a-chronic-asthma-model
#13
M Y Ozkars, O Keskin, M Tokur, M Ulasli, B Gogebakan, H Ciralik, E Kucukosmanoglu, C Demirel, S Oztuzcu, H Kahraman
BACKGROUND: Corticosteroids are used in the treatment of asthma. The aim of this study was to determine the efficacy of anti-IgE and anti-TNF alpha as asthma treatments. METHODS: A mouse model of chronic asthma was developed. The fluticasone group was exposed to fluticasone and the anti-IgE and anti-TNF groups were administered anti-IgE or anti-TNF. IL-4, and IgE levels were measured, and histological analysis, pathological analysis and miRNA-126, miRNA-133a analyses were applied...
November 27, 2017: Allergologia et Immunopathologia
https://www.readbyqxmd.com/read/29173443/omalizumab-treatment-for-allergic-bronchopulmonary-aspergillosis-in-young-patients-with-cystic-fibrosis
#14
Caroline Perisson, Leila Destruys, Dominique Grenet, Laurence Bassinet, Jocelyne Derelle, Isabelle Sermet-Gaudelus, Caroline Thumerelle, Anne Prevotat, Vincent Rosner, Annick Clement, Harriet Corvol
BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) is a severe lung disease complication caused by an Aspergillus fumigatus-induced hypersensitivity that affects 2-15% of patients with cystic fibrosis (CF). The mainstay treatment consists of a combination of corticosteroids and antifungals. However, repeated or long-term corticosteroid therapies can lead to serious side effects. The monoclonal anti-IgE antibody, omalizumab, has demonstrated its efficacy in allergic asthma. As ABPA results from a hypersensitivity to a specific allergen, omalizumab might benefit CF patients with ABPA...
December 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/29172299/the-effect-of-anti-ige-therapy-in-knee-osteoarthritis-a-pilot-observational-study
#15
A Aquili, L Farinelli, C Bottegoni, L Antonicelli, A Gigante
Osteoarthritis is a whole-joint disease and its pathogenesis remains poorly understood. Recent evidence proposed the importance of the innate immune system as trigger of synovium inflammation following the degeneration of cartilage. Moreover, synovial mast cells (MCs) might be correlated with pain and disability reported by patients. Anti IgE therapy represents a new class of MCs stabilizing agent, licensed for people with asthma and chronic urticaria. Therefore, we studied if the stabilizing effect of anti IgE would improve the pain and disability in patients affected by knee osteoarthritis and atopic disease...
October 2017: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/29171925/clinical-and-photobiological-response-in-eight-patients-with-solar-urticaria-under-treatment-with-omalizumab-and-review-of-the-literature
#16
Daniel Morgado-Carrasco, Xavier Fustà-Novell, Sebastian Podlipnik, Andrea Combalia, Paula Aguilera
BACKGROUND: Solar urticaria (SU) is a rare photodermatosis. Treatment is challenging, and outcomes are often disappointing. Omalizumab is an anti-IgE, currently approved for treatment of chronic spontaneous urticaria. We sought to evaluate therapy with omalizumab in refractory SU and describe predictive factors for response. MATERIALS/METHODS: Patients with refractory SU under treatment with omalizumab were included in this study. Clinical outcome was evaluated using the Urticaria Activity Score 7 (UAS7), Dermatology Life Quality Index (DLQI) and Pruritus Visual Analogue Scale (VAS)...
November 24, 2017: Photodermatology, Photoimmunology & Photomedicine
https://www.readbyqxmd.com/read/29150253/anti-ige-or-anti-il5-that-is-the-question
#17
REVIEW
Elliot Israel, Reynold A Panettieri
No abstract text is available yet for this article.
November 14, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29124807/combining-anti-ige-with-oral-immunotherapy
#18
EDITORIAL
Valérie Trendelenburg, Kirsten Beyer
No abstract text is available yet for this article.
November 2017: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/29106996/chronic-rhinosinusitis-endotypes-biomarkers-and-treatment-response
#19
Jose Gurrola, Larry Borish
It is increasingly recognized that chronic rhinosinusitis (CRS) comprises a spectrum of different diseases with distinct clinical presentations and pathogenic mechanisms. Defining the distinct phenotypes and endotypes of CRS impacts prognosis and most importantly is necessary as the basis for making therapeutic decisions. The need for individualized defining of pathogenic mechanisms prior to initiating therapy extends to virtually all therapeutic considerations. This is clearly crucial with antibiotics where, barring an influence from their off-target anti-inflammatory pharmacological effects, an understanding of the role of individual biome predicts likelihood of therapeutic benefit...
October 26, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29102514/efficacy-and-safety-of-omalizumab-for-the-treatment-of-refractory-chronic-spontaneous-urticaria-in-japanese-patients-subgroup-analysis-of-the-phase-3-polaris-study
#20
Michihiro Hide, Atsuyuki Igarashi, Akiko Yagami, Yuko Chinuki, Naoko Inomata, Atsushi Fukunaga, Guenther Kaiser, Junyi Wang, Soichiro Matsushima, Steven Greenberg, Sam Khalil
BACKGROUND: Omalizumab, a humanized anti-IgE monoclonal antibody, proved efficacious and well tolerated in patients with chronic spontaneous urticaria (CSU) refractory to H1 antihistamines (H1AH) in the POLARIS study (NCT02329223), a randomized, double-blind, placebo-controlled trial in East Asian patients. However, data in Japanese patients, who have specific baseline characteristics (e.g., low angioedema incidence, different background medications) that may impact clinical outcomes, are lacking...
November 1, 2017: Allergology International: Official Journal of the Japanese Society of Allergology
keyword
keyword
41626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"